デフォルト表紙
市場調査レポート
商品コード
1448346

スペシャリティジェネリックの世界市場規模、シェア、成長分析:タイプ別、用途別 - 産業予測(2024年~2031年)

Global Specialty Generics Market Size, Share, Growth Analysis, By Type(Oral, injectable), By Application(Oncology, neurology) - Industry Forecast 2024-2031

出版日: | 発行: SkyQuest | ページ情報: 英文 182 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
スペシャリティジェネリックの世界市場規模、シェア、成長分析:タイプ別、用途別 - 産業予測(2024年~2031年)
出版日: 2024年03月06日
発行: SkyQuest
ページ情報: 英文 182 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 目次
概要

世界のスペシャリティジェネリックの市場規模は、2022年に733億8,000万米ドルとなり、2023年の801億3,000万米ドルから2031年には1,620億2,000万米ドルに拡大し、予測期間中(2024年~2031年)にCAGR9.2%で成長すると予測されています。

スペシャリティジェネリック、または特定の疾患を治療するために設計された特許切れ医薬品は、スペシャリティジェネリックの世界市場に含まれています。同市場の拡大は、ヘルスケアコスト削減への取り組み、特許切れ、有名ブランド薬の手頃な代替品へのニーズの高まりが背景にあります。この市場の特徴は、複雑な製剤、幅広い治療領域、規制上の障害です。また、リーズナブルな価格で治療薬を提供できる可能性があるというメリットもあります。製薬企業が開発、生産、コンプライアンスに集中するにつれ、戦略的買収や提携の重要性はさらに高まっています。市場の将来は、革新的で利用しやすい治療法の開拓、ヘルスケア政策の変化、価格とドラッグデリバリー技術への圧力によって形作られます。

目次

エグゼクティブサマリー

  • 市場概要
  • 転変

調査手法

  • 情報調達
  • 二次・一次情報源
  • 市場規模の推定
  • 市場の前提条件と制限

親市場の分析

  • 市場概要
  • 市場規模
  • 市場力学
    • 促進要因
    • 機会
    • 抑制要因
    • 課題

主な市場の考察

  • 技術分析
  • 価格分析
  • サプライチェーン分析
  • バリューチェーン分析
  • 市場のエコシステム
  • IP分析
  • 貿易分析
  • スタートアップ分析
  • 原材料の分析
  • イノベーションマトリクス
  • パイプライン製品の分析
  • マクロ経済指標
  • 主な投資の分析
  • 主な成功要因
  • 競合の程度

市場力学と見通し

  • 市場力学
    • 促進要因
    • 機会
    • 抑制要因
    • 課題
  • 規制情勢
  • ポーターの分析
  • 将来の混乱についての特別な考察

スペシャリティジェネリックの世界市場:タイプ別

  • 市場概要
  • 経口
  • 注射
  • 局所
  • その他

スペシャリティジェネリックの世界市場:用途別

  • 市場概要
  • 腫瘍学
  • 神経学
  • 自己免疫疾患
  • その他

スペシャリティジェネリックの世界市場規模:地域別

  • 市場概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • スペイン
    • フランス
    • 英国
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • ラテンアメリカ
    • ブラジル
    • その他ラテンアメリカ
  • 中東・アフリカ(MEA)
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ

競合情勢

  • 上位5社の比較
  • 主要企業の市場ポジショニング(2021年)
  • 主要市場企業が採用した戦略
  • 主要成功戦略
  • 市場における最近の活動
  • 主要企業の市場シェア(2021年)

主要企業プロファイル

  • Teva Pharmaceutical Industries Ltd-Israel
  • Mylan N.V.-USA
  • Sandoz International GmbH(a division of Novartis)-Switzerland
  • Sun Pharmaceutical Industries Ltd-India
  • Lupin Limited-India
  • Dr. Reddy's Laboratories Ltd-India
  • Apotex Inc.-Canada
  • Endo International plc-Ireland
  • Aspen Pharmacare Holdings Limited-South Africa
  • Mayne Pharma Group Limited-Australia
  • Perrigo Company plc-Ireland
  • Glenmark Pharmaceuticals Ltd-India
  • Amneal Pharmaceuticals LLC-USA
  • Hikma Pharmaceuticals PLC-Jordan
  • Fresenius Kabi AG-Germany
  • Aurobindo Pharma Limited-India
  • Zydus Cadila-India
  • Cipla Limited-India
  • Torrent Pharmaceuticals Ltd-India
  • Alvogen-USA
目次
Product Code: SQMIG55E2036

Global Specialty Generics Market size was valued at USD 73.38 billion in 2022 and is poised to grow from USD 80.13 billion in 2023 to USD 162.02 billion by 2031, growing at a CAGR of 9.2% during the forecast period (2024-2031).

Specialty generics, or off-patent pharmaceuticals designed to treat certain ailments, are included in the Global Specialty Generics Market. Its expansion is driven by efforts to reduce healthcare costs, patent expirations, and the growing need for affordable substitutes for name-brand medications. This market is distinguished by complicated formulations, a wide range of therapeutic areas, and regulatory obstacles. It also benefits from the possibility of providing reasonably priced remedies. Strategic acquisitions and alliances become even more important as pharmaceutical businesses concentrate on development, production, and compliance. The market's future is shaped by the development of innovative and accessible therapies, changing healthcare policy, and pressures on prices and drug delivery technology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Specialty Generics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Specialty Generics Market Segmental Analysis

Type, application, and geography are the three main ways to divide up the worldwide specialty generics market. Oral, injectable, topical, and other forms are available to accommodate different preferences for administration. Applications include illnesses of the central nervous system, cardiology, and cancer. North America, Europe, Asia-Pacific, and the rest of the globe make up the market's geographical boundaries.

Drivers of the Global Specialty Generics Market

Specialty generics are a popular choice for consumers and healthcare professionals looking for cost-effective treatment options because they are frequently less expensive than name-brand specialty medications. The need for reasonably priced drugs, particularly for complicated and long-term ailments, fuels the expansion of the specialty generics industry as healthcare expenses keep rising.

Restraints in the Global Specialty Generics Market

Complex production procedures, delivery systems, and formulations are frequently used in specialty generics. These drugs can be difficult to develop and produce, requiring specific knowledge and facilities. Due to its complexity, fewer manufacturers may be able to produce these generics, which could result in a lack of supply.

Market Trends of the Global Specialty Generics Market

The intricacy of specialty generics is what sets them apart; they frequently have complex formulations, delivery systems, or manufacturing procedures. The increasing need for complicated generics, which are more difficult to create and produce than conventional generic medications, was one significant trend. When compared to their name-brand equivalents, these sophisticated generics can save a considerable amount of money, but they frequently demand a greater degree of experience and effort. Biosimilars, transdermal patches, inhalation devices, and extended-release formulations are a few examples. Specialty generics, which addressed a range of therapeutic areas like oncology, disorders of the central nervous system, and autoimmune diseases, were becoming more and more prevalent in the market.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Specialty Generics Market by Type

  • Market Overview
  • Oral
  • injectable
  • topical
  • and others

Global Specialty Generics Market by Application

  • Market Overview
  • Oncology
  • neurology
  • autoimmune diseases
  • and others

Global Specialty Generics Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Teva Pharmaceutical Industries Ltd - Israel
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V. - USA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sandoz International GmbH (a division of Novartis) - Switzerland
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd - India
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lupin Limited - India
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd - India
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Apotex Inc. - Canada
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Endo International plc - Ireland
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aspen Pharmacare Holdings Limited - South Africa
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mayne Pharma Group Limited - Australia
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Perrigo Company plc - Ireland
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Glenmark Pharmaceuticals Ltd - India
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amneal Pharmaceuticals LLC - USA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hikma Pharmaceuticals PLC - Jordan
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fresenius Kabi AG - Germany
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aurobindo Pharma Limited - India
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zydus Cadila - India
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cipla Limited - India
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Torrent Pharmaceuticals Ltd - India
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alvogen - USA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments